Rapamycin reverses paraquat-induced acute lung injury in a rat model through inhibition of NFκB activation

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 5, 2015, Pages 4627-4638

  Chen, Da ^a   Ma, Tao ^a   Liu, Xiao Wei ^a   Yang, Chen ^a   Liu, Zhi ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Acute lung injury; Glutathione peroxidase; Malondialdehyde; NF B; Paraquat; Paraquat induced acute lung injury rat model; Rapamycin; Superoxide dismutase

Indexed keywords

BIOLOGICAL MARKER; CARBON DIOXIDE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PARAQUAT; RAPAMYCIN; SUPEROXIDE DISMUTASE;

ACUTE LUNG INJURY; ANIMAL; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; CHEMICALLY INDUCED; CHEMISTRY; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; LUNG; MALE; METABOLISM; NEUTROPHIL; PATHOLOGY; PH; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TIME FACTOR;

ACUTE LUNG INJURY; ANIMALS; BIOMARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CARBON DIOXIDE; DISEASE MODELS, ANIMAL; GLUTATHIONE PEROXIDASE; HYDROGEN-ION CONCENTRATION; LUNG; MALE; MALONDIALDEHYDE; NEUTROPHILS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARAQUAT; PHOSPHORYLATION; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SIROLIMUS; SUPEROXIDE DISMUTASE; TIME FACTORS;

EID: 84937792822     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Liu XW, Ma T, Qu B, Ji Y and Liu Z. Prognostic value of initial arterial lactate level and lactate metabolic clearance rate in patients with acute paraquat poisoning. Am J Emerg Med 2013; 31: 1230-1235.
2. Zhang J, Lv G and Zhao Y. The significance of serum xanthine oxidase and oxidation markers in acute paraquat poisoning in humans. Clin Biochem 2011; 44: 221-225.
3. Gawarammana IB and Dawson AH. Peripheral burning sensation: a novel clinical marker of poor prognosis and higher plasma-paraquat concentrations in paraquat poisoning. Clin Toxicol (Phila) 2010; 48: 347-349.
4. Dinis-Oliveira RJ, Duarte JA, Sanchez-Navarro A, Remiao F, Bastos ML and Carvalho F. Paraquat poisonings: mechanisms of lung toxicity, clinical features, and treatment. Crit Rev Toxicol 2008; 38: 13-71.
5. Lee K, Park EK, Stoecklin-Marois M, Koivunen ME, Gee SJ, Hammock BD, Beckett LA and Schenker MB. Occupational paraquat exposure of agricultural workers in large Costa Rican farms. Int Arch Occup Environ Health 2009; 82: 455-462.
6. Omura T, Asari M, Yamamoto J, Oka K, Hoshina C, Maseda C, Awaya T, Tasaki Y, Shiono H, Yonezawa A, Masuda S, Matsubara K and Shimizu K. Sodium tauroursodeoxycholate prevents paraquat-induced cell death by suppressing endoplasmic reticulum stress responses in human lung epithelial A549 cells. Biochem Biophys Res Commun 2013; 432: 689-694.
7. Lee Y, Lee JH, Seong AJ, Hong CK, Lee HJ, Shin DH and Hwang SY. Arterial lactate as a predictor of mortality in emergency department patients with paraquat intoxication. Clin Toxicol (Phila) 2012; 50: 52-56.
8. Hsieh YW, Lin JL, Lee SY, Weng CH, Yang HY, Liu SH, Wang IK, Liang CC, Chang CT and Yen TH. Paraquat poisoning in pediatric patients. Pediatr Emerg Care 2013; 29: 487-491.
9. Kang MS, Gil HW, Yang JO, Lee EY and Hong SY. Comparison between kidney and hemoperfusion for paraquat elimination. J Korean Med Sci 2009; 24 Suppl: S156-160.
10. Hong SY, Yang JO, Lee EY and Kim SH. Effect of haemoperfusion on plasma paraquat concentration in vitro and in vivo. Toxicol Ind Health 2003; 19: 17-23.
11. Gil HW, Kang MS, Yang JO, Lee EY and Hong SY. Association between plasma paraquat level and outcome of paraquat poisoning in 375 paraquat poisoning patients. Clin Toxicol (Phila) 2008; 46: 515-518.
12. Jo YH, Kim K, Rhee JE, Suh GJ, Kwon WY, Na SH and Alam HB. Therapeutic hypothermia attenuates acute lung injury in paraquat intoxication in rats. Resuscitation 2011; 82: 487-491.
13. Wang BL, Tu YY, Fu JF, Zhong YX, Fu GQ, Tian XX, Wang LH, Gong L and Ren QY. Unbalanced MMP/TIMP-1 expression during the development of experimental pulmonary fibrosis with acute paraquat poisoning. Mol Med Rep 2011; 4: 243-248.
14. Kim EK and Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405.
15. Chen Y, Nie YC, Luo YL, Lin F, Zheng YF, Cheng GH, Wu H, Zhang KJ, Su WW, Shen JG and Li PB. Protective effects of naringin against paraquat-induced acute lung injury and pulmonary fibrosis in mice. Food Chem Toxicol 2013; 58: 133-140.
16. Qiu QM, Liu Y, Song Q, Ge Y, Hong GL, Lu ZQ, Liang H and Li MF. [Effects of hemoperfusion on oxidative stress, matrix metalloproteinases and their inhibitors in acute paraquat poisoning rabbits]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2012; 30: 89-96.
17. Fielhaber JA, Carroll SF, Dydensborg AB, Shourian M, Triantafillopoulos A, Harel S, Hussain SN, Bouchard M, Qureshi ST and Kristof AS. Inhibition of mammalian target of rapamycin augments lipopolysaccharide-induced lung injury and apoptosis. J Immunol 2012; 188: 4535-4542.
18. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, Marto JA and Sabatini DM. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011; 332: 1317-1322.
19. Huang J and Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009; 37: 217-222.
20. Zoncu R, Efeyan A and Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
21. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009; 196: 65-80.
22. Yu K and Toral-Barza L. Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor. Methods Mol Biol 2012; 821: 15-28.
23. Soll C and Clavien PA. Inhibition of mammalian target of rapamycin: the janus face of immunosuppression? Hepatology 2010; 51: 1113-1115.
24. Haidinger M, Poglitsch M, Geyeregger R, Kasturi S, Zeyda M, Zlabinger GJ, Pulendran B, Horl WH, Saemann MD and Weichhart T. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 2010; 185: 3919-3931.
25. Strozyk E and Kulms D. The role of AKT/mTOR pathway in stress response to UV-irradiation: implication in skin carcinogenesis by regulation of apoptosis, autophagy and senescence. Int J Mol Sci 2013; 14: 15260-15285.
26. Buitrago-Molina LE and Vogel A. mTor as a potential target for the prevention and treatment of hepatocellular carcinoma. Curr Cancer Drug Targets 2012; 12: 1045-1061.
27. Chaveroux C, Eichner LJ, Dufour CR, Shatnawi A, Khoutorsky A, Bourque G, Sonenberg N and Giguere V. Molecular and genetic crosstalks between mTOR and ERRalpha are key determinants of rapamycin-induced nonalcoholic fatty liver. Cell Metab 2013; 17: 586-598.
28. National Research Council (US) Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academies Press (US); 1996.
29. Mitsopoulos P and Suntres ZE. Cytotoxicity and gene array analysis of alveolar epithelial A549 cells exposed to paraquat. Chem Biol Interact 2010; 188: 427-436.
30. He X, Wang L, Szklarz G, Bi Y and Ma Q. Resveratrol inhibits paraquat-induced oxidative stress and fibrogenic response by activating the nuclear factor erythroid 2-related factor 2 pathway. J Pharmacol Exp Ther 2012; 342: 81-90.
31. Lacerda AC, Rodrigues-Machado Mda G, Mendes PL, Novaes RD, Carvalho GM, Zin WA, Gripp F and Coimbra CC. Paraquat (PQ)-induced pulmonary fibrosis increases exercise metabolic cost, reducing aerobic performance in rats. J Toxicol Sci 2009; 34: 671-679.
32. Caruso M, Alamo A, Crisafulli E, Raciti C, Fisichella A and Polosa R. Adenosine signaling pathways as potential therapeutic targets in respiratory disease. Expert Opin Ther Targets 2013; 17: 761-772.
33. Guzel A, Kanter M, Guzel A, Pergel A and Erboga M. Anti-inflammatory and antioxidant effects of infliximab on acute lung injury in a rat model of intestinal ischemia/reperfusion. J Mol Histol 2012; 43: 361-369.
34. Ciuffreda L, Di Sanza C, Incani UC and Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 2010; 10: 484-495.
35. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Basecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M and McCubrey JA. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011; 3: 192-222.
36. Liu Y, Vertommen D, Rider MH and Lai YC. Mammalian target of rapamycin-independent S6K1 and 4E-BP1 phosphorylation during contraction in rat skeletal muscle. Cell Signal 2013; 25: 1877-1886.
37. Wysocki PJ and Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn 2010; 10: 509-519.
38. Le Couteur DG, McLachlan AJ, Quinn RJ, Simpson SJ and de Cabo R. Aging biology and novel targets for drug discovery. J Gerontol A Biol Sci Med Sci 2012; 67: 168-174.
39. Wang Y, Wang VM and Chan CC. The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatment. Eye (Lond) 2011; 25: 127-139.
40. Greenberger S, Yuan S, Walsh LA, Boscolo E, Kang KT, Matthews B, Mulliken JB and Bischoff J. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol 2011; 131: 2467-2476.
41. Pfafflin A and Schleicher E. Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem 2009; 393: 1473-1480.
42. Nakajima S, Hiramatsu N, Hayakawa K, Saito Y, Kato H, Huang T, Yao J, Paton AW, Paton JC and Kitamura M. Selective abrogation of BiP/GRP78 blunts activation of NF-kappaB through the ATF6 branch of the UPR: involvement of C/EBPbeta and mTOR-dependent dephosphorylation of Akt. Mol Cell Biol 2011; 31: 1710-1718.
43. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP and Baldwin AS. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008; 22: 1490-1500.
44. Hou YC, Chiu WC, Yeh CL and Yeh SL. Glutamine modulates lipopolysaccharide-induced activation of NF-kappaB via the Akt/mTOR pathway in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2012; 302: L174-183.
45. Zhang L, Ma J and Liu H. Protective effect of ischemic postconditioning against ischemia reperfusion-induced myocardium oxidative injury in IR rats. Molecules 2012; 17: 3805-3817.
46. Frizzola M, Miller TL, Rodriguez ME, Zhu Y, Rojas J, Hesek A, Stump A, Shaffer TH and Dysart K. High-flow nasal cannula: impact on oxygenation and ventilation in an acute lung injury model. Pediatr Pulmonol 2011; 46: 67-74.